Brutvan Tomas, Kotasova Marcela, Krausova Adela, Krizova Jarmila, Psenicka Otakar, Sevcik Jan, Sevcik Martin, Vitkova Hana, Jezkova Jana
3rd Department of Internal Medicine, General University Hospital in Prague and The 1st Faculty of Medicine of Charles University, Prague, Czech Republic.
Institute of Clinical Biochemistry and Laboratory Medicine, General University Hospital in Prague and The 1st Faculty of Medicine of Charles University, Prague, Czech Republic.
Endocr Connect. 2025 Sep 4;14(9). doi: 10.1530/EC-25-0281. Print 2025 Sep 1.
The overnight dexamethasone suppression test (DST) is recommended for the initial testing of Cushing's syndrome. Simultaneous measurement of dexamethasone and cortisol is recommended. This study aimed to determine the cutoff value for dexamethasone measured in DST analyzed via liquid chromatography tandem mass spectrometry (2D-LC-MS/MS) and to assess whether analysis of adrenal steroids other than cortisol may improve diagnostic accuracy.
A prospective study was conducted including patients with adrenal incidentalomas (n = 55), pituitary incidentalomas and symptoms of Cushing's disease (n = 18), and healthy controls (n = 100) undergoing DST. Plasma levels of ten steroids and dexamethasone were determined via 2D-LC-MS/MS, while cortisol levels were also determined via a chemiluminescence immunoassay.
The lower 2.5th percentile of plasma dexamethasone in the control group (cortisol level <50 nmol/L) was 3.48 nmol/L, which was set as the cutoff. In the subgroup of patients with adrenal incidentalomas, regardless of the results of DST, subjects exhibited identical changes in the basal adrenal steroid profile: increased 11-deoxycortisol and decreased DHEA and DHEAS levels. After 1 mg dexamethasone administration, cortisol and cortisone levels increased, while decreased androstenedione and 17-OHP levels were detected. Statistically significant changes were found in the subgroup of patients with pituitary incidentalomas: increased levels of 11-deoxycortisol, plasma cortisol, cortisone, and androstenedione were observed only in those with serum cortisol levels >50 nmol/L. Based on the ROC curves, none of the steroid hormones exhibited higher specificity than cortisol.
Simultaneous measurement of cortisol and dexamethasone increases DST specificity. The cutoff value for dexamethasone was set at 3.48 nmol/L. None of the adrenal steroids in the DST demonstrated increased specificity; thus, a cortisol concentration <50 nmol/L remains the gold standard for ruling out Cushing's syndrome.
过夜地塞米松抑制试验(DST)推荐用于库欣综合征的初始检测。建议同时测量地塞米松和皮质醇。本研究旨在确定通过液相色谱串联质谱法(2D-LC-MS/MS)分析的DST中所测地塞米松的临界值,并评估除皮质醇外的肾上腺类固醇分析是否可提高诊断准确性。
进行了一项前瞻性研究,纳入了患有肾上腺偶发瘤的患者(n = 55)、患有垂体偶发瘤且有库欣病症状的患者(n = 18)以及接受DST的健康对照者(n = 100)。通过2D-LC-MS/MS测定十种类固醇和地塞米松的血浆水平,同时通过化学发光免疫测定法测定皮质醇水平。
对照组(皮质醇水平<50 nmol/L)血浆地塞米松的第2.5百分位数下限为3.48 nmol/L,将其设定为临界值。在肾上腺偶发瘤患者亚组中,无论DST结果如何,受试者基础肾上腺类固醇谱均呈现相同变化:11-脱氧皮质醇升高,脱氢表雄酮(DHEA)和硫酸脱氢表雄酮(DHEAS)水平降低。给予1 mg地塞米松后,皮质醇和可的松水平升高,同时检测到雄烯二酮和17-羟孕酮(17-OHP)水平降低。在垂体偶发瘤患者亚组中发现了具有统计学意义 的变化:仅在血清皮质醇水平>50 nmol/L的患者中观察到11-脱氧皮质醇、血浆皮质醇、可的松和雄烯二酮水平升高。基于ROC曲线,没有一种类固醇激素表现出比皮质醇更高的特异性。
同时测量皮质醇和地塞米松可提高DST的特异性。地塞米松的临界值设定为3.48 nmol/L。DST中的肾上腺类固醇均未显示特异性增加;因此,皮质醇浓度<50 nmol/L仍然是排除库欣综合征的金标准。